ZA963743B - Transdermal therapeutic system (TTS) for the administration of testosterone - Google Patents

Transdermal therapeutic system (TTS) for the administration of testosterone

Info

Publication number
ZA963743B
ZA963743B ZA963743A ZA963743A ZA963743B ZA 963743 B ZA963743 B ZA 963743B ZA 963743 A ZA963743 A ZA 963743A ZA 963743 A ZA963743 A ZA 963743A ZA 963743 B ZA963743 B ZA 963743B
Authority
ZA
South Africa
Prior art keywords
testosterone
therapeutic system
tts
administration
transdermal therapeutic
Prior art date
Application number
ZA963743A
Inventor
Wilfried Fischer
Daniel Bracher
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of ZA963743B publication Critical patent/ZA963743B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention concerns a transdermal therapeutic system for administering testosterone or a testosterone derivative as the active substance.
ZA963743A 1995-05-10 1996-05-10 Transdermal therapeutic system (TTS) for the administration of testosterone ZA963743B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19517145A DE19517145C2 (en) 1995-05-10 1995-05-10 Transdermal therapeutic system (TTS) for administration of testosterone

Publications (1)

Publication Number Publication Date
ZA963743B true ZA963743B (en) 1996-11-18

Family

ID=7761562

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA963743A ZA963743B (en) 1995-05-10 1996-05-10 Transdermal therapeutic system (TTS) for the administration of testosterone

Country Status (17)

Country Link
EP (1) EP0825865B1 (en)
JP (1) JPH11504643A (en)
CN (1) CN1183723A (en)
AT (1) ATE208200T1 (en)
AU (1) AU702710B2 (en)
BR (1) BR9608255A (en)
CA (1) CA2220358A1 (en)
CZ (1) CZ287678B6 (en)
DE (2) DE19517145C2 (en)
DK (1) DK0825865T3 (en)
HU (1) HUP9801130A3 (en)
NO (1) NO975140L (en)
NZ (1) NZ308516A (en)
PL (1) PL323145A1 (en)
SK (1) SK149797A3 (en)
WO (1) WO1996035427A1 (en)
ZA (1) ZA963743B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1429697A (en) * 1995-12-29 1997-07-28 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
CA2259407C (en) * 1996-07-03 2006-04-04 Alza Corporation Drug delivery devices and process of manufacture
DE19646050A1 (en) * 1996-11-08 1998-05-14 Labtec Gmbh Transdermal therapeutic system e.g. containing testosterone, melatonin
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
EP1079815B1 (en) * 1998-05-22 2004-10-20 Novosis AG Timed-release transdermal systems containing an active ingredient
FR2793689B1 (en) * 1999-05-19 2001-08-24 Pf Medicament TRANSDERMAL DEVICE FOR THE ADMINISTRATION OF TESTOSTERONE OR A DERIVATIVE THEREOF
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US8173155B2 (en) 2004-06-01 2012-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
TR201815853T4 (en) 2005-10-12 2018-11-21 Besins Healthcare Sarl Testosterone gel for use in the treatment of hypogonadism.
FR2895679B1 (en) * 2005-12-29 2012-06-08 Pf Medicament STABILIZATION OF TESTOSTERONE IN TRANSDERMAL DEVICES
CN101480399B (en) * 2008-09-25 2011-10-05 宋博 Application of andrusol in preparing medicament for treating asthenospermia
DE102011012712A1 (en) 2011-03-01 2012-09-06 Frank Lehmann-Horn Use of aldosterone receptor antagonists for the treatment of female sexual dysfunction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
GB8804164D0 (en) * 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
MX9202350A (en) * 1991-05-20 1992-11-01 Alza Corp SKIN PENETRATION INCREMENTING COMPOSITIONS USING GLYCEROL MONOLINOLEATE.
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
JPH08501529A (en) * 1992-06-11 1996-02-20 セラテック・インコーポレイテッド Use of glycerin to alleviate skin-penetrating drug administration
CA2161004C (en) * 1993-04-20 2004-10-26 Wilfried Fischer Active ingredient patch
DE4313402A1 (en) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermal preparation of active compound
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women

Also Published As

Publication number Publication date
CZ287678B6 (en) 2001-01-17
CZ351297A3 (en) 1998-03-18
CN1183723A (en) 1998-06-03
DE19517145C2 (en) 2000-02-24
NO975140L (en) 1997-11-10
SK149797A3 (en) 1998-05-06
NO975140D0 (en) 1997-11-07
CA2220358A1 (en) 1996-11-14
HUP9801130A3 (en) 2001-03-28
AU702710B2 (en) 1999-03-04
PL323145A1 (en) 1998-03-16
WO1996035427A1 (en) 1996-11-14
EP0825865B1 (en) 2001-11-07
DE19517145C1 (en) 1996-11-28
DE59608150D1 (en) 2001-12-13
AU5805096A (en) 1996-11-29
BR9608255A (en) 1999-02-02
HUP9801130A2 (en) 1998-08-28
NZ308516A (en) 1999-05-28
JPH11504643A (en) 1999-04-27
DK0825865T3 (en) 2002-02-18
ATE208200T1 (en) 2001-11-15
EP0825865A1 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
UA29476C2 (en) Transdermal therapeutic system, containing estradiol
EP0744942A4 (en) Controlled release hydrogel formulation
AU5397996A (en) Iontophoretic transdermal system for the administration of at least two substances
AU7289694A (en) Three part device for the transdermic administration of drugs by electrophoresis or iontophoresis
ZA963743B (en) Transdermal therapeutic system (TTS) for the administration of testosterone
HU9203871D0 (en) Pharmaceutical application of certain cistine derivatives
AU4170197A (en) Pharmaceutical compounds
GB9212308D0 (en) Therapeutic compositions
ZA942872B (en) Transdermal therapeutic systems for administering active substances
HUP9903348A3 (en) Transdermal therapeutic system (tts) for administering active substances for the teratment of drug dependency or drug addiction
AU1469097A (en) Pharmaceutical compounds
CA2331414A1 (en) Transdermal therapeutic system for the administration of candesartan
IL96506A0 (en) Transdermal system for administering pharmaceutical compounds under ph control
ZA963744B (en) Topical aciclovir preparation
ZA966083B (en) Agent for transdermal administration containing esters of 13-ethyl-17ß-hydroxy-11-methylene-18,19-dinor-17Ó-pregn-4-en-20-yn-3-one.
ES2184121T3 (en) FORMULATION FOR THE TREATMENT AND / OR PROFILAXIS OF DEMENTIA.
SI0859595T1 (en) Therapeutic preparation for the transdermal administration of active substances
MX9801604A (en) Pharmaceutical compounds.
UA23119A (en) Psychotropic agent
AP9600780A0 (en) Process for the preparation of peroxetine hydrochloride anhydrate and its use as therapeutic agent.